Articles producció científica> Medicina i Cirurgia

Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study

  • Dades identificatives

    Identificador: imarina:9287581
    Handle: https://hdl.handle.net/20.500.11797/imarina9287581
    Autors:
    Villarroel, PGPadro, JGMarquina, GJanez, NMGonzalez, EEAnton, ASanchez, MBCaceres, ARLopez-Lopez, RCornejo, REGarcia, PBFabregat, RMFernandez, BCBermudo, CLCamps, C
    Resum:
    Aim: To evaluate the quality of life (QoL) in patients with breakthrough cancer pain (BTcP) in Spanish medical oncology departments. Patients & methods: In a prospective, observational, multicenter study, we assessed QoL using the EQ-5D-5L instrument at baseline and after 15 and 30 days of individualized BTcP therapy, as well as BTcP characteristics and treatment. Results: Patients (n = 118) were mainly women, over 64 years old and with advanced cancer. QoL improved at 15 (p = 0.013) and 30 days (p = 0.011) versus baseline. Individualized BTcP therapy consisted mostly of rapid-onset opioids (transmucosal fentanyl at doses of 67-800 μg) according to the physician evaluation. BTcP improved, including statistically significant reductions in intensity, duration, number of episodes in the last 24 h and time to onset of BTcP relief. Conclusion: QoL increased after individualized pain therapy in patients with advanced cancer and BTcP in medical oncology departments.

  • Altres:

    Autor segons l'article: Villarroel, PG; Padro, JG; Marquina, G; Janez, NM; Gonzalez, EE; Anton, A; Sanchez, MB; Caceres, AR; Lopez-Lopez, R; Cornejo, RE; Garcia, PB; Fabregat, RM; Fernandez, BC; Bermudo, CL; Camps, C
    Departament: Medicina i Cirurgia
    Autor/s de la URV: Gumà Padró, José
    Paraules clau: Transmucosal fentanyl Rapid-onset opioids Quality of life Medical oncology Management Breakthrough cancer pain transmucosal fentanyl scale rapid-onset opioids quality of life medical oncology
    Resum: Aim: To evaluate the quality of life (QoL) in patients with breakthrough cancer pain (BTcP) in Spanish medical oncology departments. Patients & methods: In a prospective, observational, multicenter study, we assessed QoL using the EQ-5D-5L instrument at baseline and after 15 and 30 days of individualized BTcP therapy, as well as BTcP characteristics and treatment. Results: Patients (n = 118) were mainly women, over 64 years old and with advanced cancer. QoL improved at 15 (p = 0.013) and 30 days (p = 0.011) versus baseline. Individualized BTcP therapy consisted mostly of rapid-onset opioids (transmucosal fentanyl at doses of 67-800 μg) according to the physician evaluation. BTcP improved, including statistically significant reductions in intensity, duration, number of episodes in the last 24 h and time to onset of BTcP relief. Conclusion: QoL increased after individualized pain therapy in patients with advanced cancer and BTcP in medical oncology departments.
    Àrees temàtiques: Oncology Odontología Medicine (miscellaneous) Medicina ii Medicina i Ciências biológicas ii Ciências biológicas i Cancer research Biotecnología Astronomia / física
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    Adreça de correu electrònic de l'autor: jose.guma@urv.cat
    Identificador de l'autor: 0000-0001-7541-9832
    Data d'alta del registre: 2024-09-07
    Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referència a l'article segons font original: Future Oncology. 18 (35): 3913-3927
    Referència de l'ítem segons les normes APA: Villarroel, PG; Padro, JG; Marquina, G; Janez, NM; Gonzalez, EE; Anton, A; Sanchez, MB; Caceres, AR; Lopez-Lopez, R; Cornejo, RE; Garcia, PB; Fabregat (2022). Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study. Future Oncology, 18(35), 3913-3927. DOI: 10.2217/fon-2022-0758
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2022
    Tipus de publicació: Journal Publications

  • Paraules clau:

    Cancer Research,Medicine (Miscellaneous),Oncology
    Transmucosal fentanyl
    Rapid-onset opioids
    Quality of life
    Medical oncology
    Management
    Breakthrough cancer pain
    transmucosal fentanyl
    scale
    rapid-onset opioids
    quality of life
    medical oncology
    Oncology
    Odontología
    Medicine (miscellaneous)
    Medicina ii
    Medicina i
    Ciências biológicas ii
    Ciências biológicas i
    Cancer research
    Biotecnología
    Astronomia / física

  • Documents:

    DocumentPrincipal

  • Cerca a google

    Search to google scholar